Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention

Stroke

Volumn 40, Issue 1, 2009, Pages 213-220

  Kettani, Fatima Zohra ^a   Dragomir, Alice ^a   Côté, Robert ^b   Roy, Louise ^a   Bérard, Anick ^a   Blais, Lucie ^a   Lalonde, Lyne ^a   Moreau, Pierre ^a   Perreault, Sylvie ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Adherence to treatment; Antihypertensive drugs; Cerebrovascular disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SENSITIVITY ANALYSIS; STROKE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; COMORBIDITY; MIDDLE AGED; PATIENT EDUCATION; RISK REDUCTION; SEX RATIO; STATISTICAL MODEL; STATISTICS;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CEREBROVASCULAR DISORDERS; COMORBIDITY; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; RISK FACTORS; RISK REDUCTION BEHAVIOR; SEX DISTRIBUTION;

EID: 60549087524     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.522193     Document Type: Article

References (28)

1. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, DeGraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2006; 113:e873-e923.
2. Heart and Stroke Foundation of Canada. The Growing Burden of Heart Disease and Stroke in Canada 2003. Ottawa: Heart and Stroke Foundation of Canada; 2003. Report No. 1-896242-30-8.
3. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 1994;50:272-298.
4. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
5. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19: 357-362.
6. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive mono-therapy in 13 managed care organizations. J Manag Care Pharm. 2006; 12:239-245.
7. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-530.
8. Statistics Canada Health Division. Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures. II edition. Ottawa: Supply and Services; 1986.
9. World Health Organization. International Classification of Diseases. Manual of the International Statistical Classification of Diseases, Injuries, and Cause of Death. 9th revision. Geneva: World Health Organization; 1977. Publication no. PHS 80-1260.
10. Régie de l'Assurance Maladie du Québec. Statistiques Annuelles (Report). Québec: Régie de l'Assurance Maladie du Québec; January 1996.
11. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol. 1995;48:999-1009.
12. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol. 2004;57:131-141.
13. Tirschwell DL, Longstreth WT Jr. Validating administrative data in stroke research. Stroke. 2002;33:2465-2470.
14. Etminan M. Pharmacoepidemiology II: the nested case-control study - a novel approach in pharmacoepidemiologic research. Pharmacotherapy. 2004;24:1105-1109.
15. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40: 1280-1288.
16. Sackett DL, Haynes RB, Gibson ES, Hackett BC, Taylor DW, Roberts RS, Johnson AL. Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet. 1975;1: 1205-1207.
17. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
18. Von KM, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197-203.
19. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol. 2005;5:5.
20. Greenland S. Sensitivity analysis, Monte Carlo risk analysis, and Bayesian uncertainty assessment. Risk Anal. 2001;21:579-583.
21. Steenland K, Greenland S. Monte Carlo sensitivity analysis and Bayesian analysis of smoking as an unmeasured confounder in a study of silica and lung cancer. Am J Epidemiol. 2004;160:384-392.
22. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihyper-tensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534-2544.
23. Li C, Engstrom G, Hedblad B, Janzon L. Sex-specific cardiovascular morbidity and mortality in a cohort treated for hypertension. J Hypertens. 2006;24:1523-1529.
24. Cox AM, McKevitt C, Rudd AG, Wolfe CD. Socioeconomic status and stroke. Lancet Neurol. 2006;5:181-188.
25. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol. 1999;149:981-983.
26. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166: 2307-2313.
27. McDermott MM, Schmitt B, Wallner E. Impact of medication nonad-herence on coronary heart disease outcomes. A critical review. Arch Intern Med. 1997;157:1921-1929.
28. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, Canning C, Platt R. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to anti-hypertensive therapy. Med Care. 1999;37:846-857.